SK bioscience and Novavax agreement
also includes production of the Novavax COVID-19 vaccine in prefilled syringe
bioscience (“Company”) announced on July 19th that the Company has
extended its partnership with Novavax, Inc. (Nasdaq: NVAX), a U.S.
biotechnology company specializing in next-generation vaccines, for the
manufacturing and supply of Novavax COVID-19 vaccine targeting Omicron variants
and in prefilled syringes.
SK bioscience and Novavax signed an agreement for the technology transfer of Novavax proprietary COVID-19 variant antigen materials and manufacturing drug substance targeting COVID-19 variants including Omicron BA.5 subvariant in response to the recent spread of SARS-CoV-2 variants.
In addition, SK Bioscience and Novavax have signed an agreement
to manufacture and supply the Novavax COVID-19 vaccine in prefilled syringe, already
loaded with the vaccine for injection. The Company will prepare the manufacturing
process this year for commercial supply of the Novavax COVID-19 vaccine in
prefilled syringe in 2023.
Stanley C. Erck, President and Chief
Executive Officer, Novavax, said, “Clinical data generated to-date demonstrate that the
Novavax COVID-19 vaccine offers broad immune responses including against
circulating variants, such as the Omicron BA.5. We are accelerating our
clinical program on Omicron BA.5 and look forward to working with SK bioscience
to bring this vaccine to market.”
Preclinical data on Omicron BA.5 will
be available in the late summer or fall, with an Omicron-containing vaccine available
by Q4 of this year.
Jaeyong Ahn, CEO of SK bioscience,
said, "We will play a role as a global vaccine hub through the contracts in
a situation where new vaccines against variants are required," adding,
"We will take the lead in protecting public health as an innovative
vaccine/bio partner based on the cooperation with various global companies, as
well as developing diverse vaccines independently."
COVID-19 vaccine is the fifth vaccine officially approved in S. Korea, and
recently became the fourth vaccine to receive emergency use authorization from
the U.S. Food and Drug Administration .